007570 — Ilyang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	324,573	343,329	371,348	383,811	370,537
Cost of Revenue
Gross Profit	178,771	181,709	204,403	216,028	200,148
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	292,063	311,175	330,030	343,429	362,184
Operating Profit	32,511	32,154	41,318	40,382	8,353
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	27,661	28,393	38,927	41,331	3,048
Provision for Income Taxes
Net Income After Taxes	19,595	21,545	25,956	31,741	112
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,985	10,880	14,384	19,238	-2,546
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,985	10,880	14,384	19,238	-2,546
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	568	673	780	1,062	452
Dividends per Share